Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY)
Clinical High Risk for Psychosis, Ultra High Risk for Psychosis, Attenuated Psychotic Symptoms
About this trial
This is an interventional treatment trial for Clinical High Risk for Psychosis focused on measuring At-Risk Mental State, Schizophrenia, Endocannabinoid System, Gut-Brain Axis, Palmitoylethanolamide, Nutraceuticals, Prevention, Early Intervention
Eligibility Criteria
Inclusion Criteria Individuals diagnosed with CHR-APS, as defined using CAARMS criteria; Aged 18-35 years; To be able to understand and communicate in Italian; To be able to give informed consent. Exclusion Criteria Lifetime history of a psychotic or manic episode lasting 7 days or longer; Active suicidal ideation indicating significant current risk or history of serious suicide attempt in the opinion of the PI, as evaluated at the screening stage; Lifetime neurological disorders (e.g., epilepsy, except febrile convulsions) or severe intercurrent physical illness; Current treatment with psychotropic medication, with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) stable monotherapy (at least 8 months); Lifetime treatment with antipsychotic medication for more than 7 days; IQ < 70; Female patients who are pregnant, lactating or not using an acceptable effective form contraception if they are at risk of falling pregnant; Taking part in another pharmacological trial.
Sites / Locations
- Unit of Psychiatry, University Hospital of UdineRecruiting
- Unit of Psychiatry, University Hospital of UdineRecruiting
Arms of the Study
Arm 1
Experimental
PEA arm
Palmitoylethanolamide (PEA)-treated patients